Skip to Content

Are you based outside North America? If yes, switch to our global website →

Application Note - Reducing your FISH probe validation burden

This application note describes the detailed clinical and analytical studies carried out to meet the performance required to achieve FDA clearance of eight probes for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

The rigorous standards required for gaining FDA clearance are recognized globally and emphasize the exceptional quality of the Cytocell FISH probes from Oxford Gene Technology (OGT).